Most studies have shown that these adjuvants are capable of enhancing the production of IL-12 through the PI3K-AKT pathway, leading to the activation of APCs, enhancement of Th1 cell function by activating the IL12-STAT4 signaling pathway, and, most importantly, induction of the cytotoxic effects of CTLs against cancer cells, which can inhibit the growth of cancer [65,67,68,70]. This evidence concerns the gene AKT1 and cancer.